Fort J A, Rios A M, Gross S, Janssen W E
Department of Pediatrics, University of Florida, Gainesville 32610.
Prog Clin Biol Res. 1990;333:185-9.
Various procedures are useful in purging bone marrow of pre-B lineage contamination prior to autologous bone marrow transplantation. Specific monoclonal antibodies are used in combination with complement, magnetic microspheres, chemotoxins, phototherapy or lectins. In this setting, the usual monoclonal antibody cocktail consists of CD9 (DU-ALL-1), CD10 (WCMH 15.14) and CD19 (HD37). Antigens reacting with all three monoclonal antibodies are present on early and mature pre-B lymphocytes. However, CD9 positive antigens have also been shown to be present on megakaryocytes, platelets and mature granulocytes. In our studies, we have found that CD10 and CD19 expression predictably vary according to disease status, with low positivity in remission and higher positivity in relapse. CD9 expression, however, varies independently of disease status and is frequently inconsistent within individual patients. As such, use of CD9 for marrow purging may result in the removal of a broad range of cell populations not related to the underlying disorder.
在自体骨髓移植前，多种程序可用于清除骨髓中的前B细胞系污染。特定的单克隆抗体与补体、磁性微球、化学毒素、光疗或凝集素联合使用。在这种情况下，常用的单克隆抗体组合包括CD9（DU-ALL-1）、CD10（WCMH 15.14）和CD19（HD37）。与所有三种单克隆抗体反应的抗原存在于早期和成熟的前B淋巴细胞上。然而，CD9阳性抗原也已被证明存在于巨核细胞、血小板和成熟粒细胞上。在我们的研究中，我们发现CD10和CD19的表达根据疾病状态可预测地变化，缓解期阳性率低，复发期阳性率高。然而，CD9的表达与疾病状态无关，并且在个体患者中经常不一致。因此，使用CD9进行骨髓净化可能会导致清除与潜在疾病无关的广泛细胞群体。
